It has been reported that IDO1 expresses in both BM and PB AML blasts [26–29], whose expression negatively correlates with clinical outcome, including the response to chemotherapy, risk of relapse and overall survival (OS) [30–33]. The gene discussed is IDO1; the disease is acute myeloid leukemia.